Extracorporeal shock wave therapy (ESWT) is a widely used non-invasive, safe, and effective treatment method in various clinical fields. In 2019, the Shockwave Medicine Committee of the Chinese Research Hospital Association released the first edition of the "Chinese Extracorporeal Shock Wave Therapy Guidelines for Musculoskeletal Diseases," which was updated in 2023. The Physical Medicine and Rehabilitation Branch of the Chinese Medical Association established the "Expert Consensus on Extracorporeal Shock Wave Therapy for Musculoskeletal Diseases" in 2019. In 2023, pain experts in China developed the "Expert Consensus on Clinical Application of Extracorporeal Shock Wave Therapy by Pain Experts in China." These guidelines have significantly contributed to standardizing ESWT's promotion and application within China. However, current expert consensus and clinical guidelines primarily focus on using ESWT for musculoskeletal diseases and chronic pain conditions, with less attention given to its application for muscle spasms, especially among children where there is no unified approach to key clinical techniques and treatment plans. Over recent years, as ESWT has been increasingly utilized in pediatric rehabilitation medicine, numerous new treatment experiences and research findings have emerged that continuously enhance the clinical evidence supporting ESWT's effectiveness in treating muscle spasms among children. Recognizing this progress, a collaboration between the Pediatric Rehabilitation Committee of China Association Rehabilitation Medicine and Shockwave Medicine Committee of Chinese Research Hospital Association led to formulating "Clinical Practice Guideline for Extracorporeal Shockwave Therapy of Muscle Spasticity in Children (2024)." This guideline aims to offer evidence-based support to practitioners specializing in pediatric rehabilitation, neurology, orthopedics when applying ESWT to treat muscle spasticity among children while promoting more standardized use of ESWT.

In 2019, the Endocrinology Branch of the Chinese Medical Association released the 2019 Chinese Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout. The emergence of the 2019 Guidelines for the Diagnosis and Treatment of Hyperuricemia and Gout ultimately led to 52 clinical issues. Using WeChat survey questionnaire format, 620 questionnaires were distributed, covering 27 provinces, autonomous regions, municipalities directly under the central government, and special administrative regions. 620 questionnaires were collected, with an effective rate of 100%. After statistical sorting, 21 clinical questions were finally identified and integrated into 19 questions to be included in the content of this guideline. Out of the final 19 clinical questions, 1 was not included due to lack of evidence, and the remaining 18 questions were merged into 12, resulting in a total of 51 recommended opinions. The selection of drugs for acute gout attacks, the selection of uric acid lowering drugs for gout patients with hyperuricemia, the selection of uric acid lowering drugs for patients with chronic kidney disease, and the selection of drugs related to hyperuricemia and gout comorbidities are partially or entirely recommended. The evidence level is C or lower, and attention should be paid to this update. As a clinical issue of concern to clinical doctors, it existed in the initial 19 question list, but was not included in the 2019 guideline generation due to the lack of any systematic evaluation and guidelines for reference. In the following five years, a large number of basic research, clinical research, and epidemiological research results urgently need to be promoted to improve the understanding and standardized diagnosis and treatment of this group of diseases among clinical physicians. At the same time, the methods for developing clinical guidelines are becoming increasingly scientific, standardized, and internationalized. Therefore, the society has decided to update the diagnosis and treatment guidelines for HUA and gout in the Chinese endocrinology profession with standardized evidence-based medicine methods and processes based on the 2019 guidelines.

Pertussis, also known as whooping cough, is a highly transmissible respiratory disease that is caused by the bacterium Bordetella pertussis (B. pertussis). Due to immunity attenuation and B. pertussis mutations after vaccination, pertussis resurgence has been reported in many developed countries with high vaccination rates. In the vaccine era, the burden of pertussis has shifted from infants to adolescents and adults in many developed countries, and they became the main source of infection for infants. According to the law of the People's Republic of China on the Prevention and Control of Infectious Diseases, pertussis is classified as a Class B infectious disease. Over the past decade, pertussis resurgence in China has attracted attention. Pertussis cases reported in China are still dominated by infant cases, and the bacterial isolates are generally resistant to macrolide antibiotics, which are different epidemiology from other countries and make some troubles for clinical management. In order to further standardize the clinical diagnosis and treatment of pertussis, this diagnosis and treatment plan was formulated based on the research progress and clinical experience at home and abroad.

There is currently no standardized guideline or industry standard for optical correction of corneal irregular astigmatism in China. This expert consensus is reached by convening domestic experts in optometry, corneal disease, and corneal refractive surgery, and conducting multiple rounds of research and expert meetings. This consensus focused on optical correction methods and combined with scientific research findings, clinical practice experience, and industry technology improvement to provide guidance and suggestions for ophthalmologists and optometrists.

This expert consensus aims to summarize the biomarkers related to skeletal muscle aging reported in previous studies from three dimensions: skeletal muscle function, structure, and body fluids. It is hoped that through these biomarkers, the degree of skeletal muscle aging can be accurately determined and the effects of aging interventions can be evaluated.